@article{4dedad0590d0464bb8bc4a953b086d92,
title = "Can ketamine be a safe option for treatment-resistant bipolar depression?",
keywords = "Ketamine, bipolar disorders, treatment-resistant bipolar depression",
author = "Balwinder Singh and {Vande Voort}, {Jennifer L.} and Frye, {Mark A.} and Simon Kung",
note = "Funding Information: A peer reviewer on this manuscript has received manuscript or speaker{\textquoteright}s fees from Astellas, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Lundbeck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Nihon Medi-Physics, Novartis, Otsuka Pharmaceutical, Shionogi, Shire, Takeda Pharmaceutical, Tsumura, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Dainippon Sumitomo Pharma, Eisai, Mochida Pharmaceutical, Meiji Seika Pharma and Shionogi. All other peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Funding Information: B Singh reports grant support from Mayo Clinic. JL Vande Voort is a co-primary investigator on an investigator-initiated study that has a grant-in-kind for supplies and genotyping only through Assurex Health. MA Frye has received Grant Support from Assurex Health, and Mayo Foundation. He also has financial interests in Chymia LLC. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ",
year = "2022",
doi = "10.1080/14740338.2022.2045272",
language = "English (US)",
volume = "21",
pages = "717--720",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",
}